AI-focused start-up Formation Bio has raised $372 million in a series D financing.
The round was led by a16z, with significant participation from Sanofi (Nasdaq: SNY) as well as Sequoia, Thrive, Emerson Collective, and others.
Scott Kupor, managing partner at a16z, and Alfred Lin, partner at Sequoia, will join the board of directors at the firm, which leverages advances in artificial intelligence to enhance drug development efficiency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze